Treatment with PPAR/PGC-1α complex agonists in mouse models of melanoma [267] and lung cancer [269] promoted FA catabolism, correlating with improved CD8+ T-cell effector function and increased acyl-CoA dehydrogenase long chain (LCAD) expression, an enzyme involved in FAO. Here, ACADL is linked to lung carcinoma.